- |||||||||| 177Lu-BiOncoFAP / Philogen, 177Lu-OncoFAP-23 / Philogen
Tumor-targeted interleukin-2 enhances the anti-cancer activity of multivalent OncoFAP radioligand therapeutics (Section 19; Poster Board #29) - Mar 14, 2023 - Abstract #AACR2023AACR_5061;
This synergy is driven by NK-cell mediated immune response directed to the tumor, with the concomitant release of granzymes and other pro-apoptotic proteins in the tumor microenvironment. Our findings heighten OncoFAP-based RLTs as promising anti-cancer drugs for treatment of FAP-positive tumors, alone or in combination with targeted interleukin-2.
|
